Syndax Pharmaceuticals (STU:1T3) Total Liabilities : €47.05 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Total Liabilities?

Syndax Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was €47.05 Mil.

Syndax Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2023 (€37.52 Mil) to Dec. 2023 (€53.81 Mil) but then declined from Dec. 2023 (€53.81 Mil) to Mar. 2024 (€47.05 Mil).

Syndax Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 (€36.54 Mil) to Dec. 2022 (€28.12 Mil) but then increased from Dec. 2022 (€28.12 Mil) to Dec. 2023 (€53.81 Mil).

Syndax Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Syndax Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Total Liabilities Chart

Syndax Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

28.73

39.81

36.54

28.12

53.81

Syndax Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															22.72	28.89	37.52	53.81	47.05

Syndax Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Syndax Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	53.274	+	(0.539	+	1.4432899320127E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	53.81

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	562.011	-	508.198
	=	53.81

Syndax Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	46.741	+	(0.307	+	2.1649348980191E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	47.05

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	499.586	-	452.538
	=	47.05

Syndax Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals (STU:1T3) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SNDX:USA

Address

35 Gatehouse Drive, Building D, Floor 3, Waltham, MA, USA, 02451

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.

Syndax Pharmaceuticals (STU:1T3) Headlines

No Headlines